{
    "clinical_study": {
        "@rank": "111075", 
        "acronym": "BDS1307", 
        "arm_group": [
            {
                "arm_group_label": "DFD01 Spray Group 1", 
                "arm_group_type": "Experimental", 
                "description": "DFD01 Spray, bid, 28 days"
            }, 
            {
                "arm_group_label": "Comp01 Lotion", 
                "arm_group_type": "Active Comparator", 
                "description": "Comp01 Lotion, bid, 14 days"
            }, 
            {
                "arm_group_label": "DFD01 Spray Group 2", 
                "arm_group_type": "Experimental", 
                "description": "DFD01 Spray, bid, 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA\n      (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily\n      for 15 days."
        }, 
        "brief_title": "DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis", 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque\n             psoriasis.\n\n          2. Subjects with psoriasis involving 20 to 50% BSA, not including the face, scalp,\n             groin, axillae and other intertriginous areas.\n\n          3. Subjects must have an IGA grade of at least 3 (moderate) at the Baseline Visit\n\n          4. Subjects whose results from the screening ACTH stimulation test are considered normal\n             (cortisol level >18 ug/dL at 30 minutes post stimulation) and show no other signs of\n             abnormal HPA function or adrenal response.  -\n\n        Exclusion Criteria:\n\n          1. Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic,\n             exfoliative or pustular psoriasis.\n\n          2. History of organ transplant requiring immunosuppression, HIV, or other\n             immunocompromised state.\n\n          3. Have received treatment for any type of cancer within 5 years of the Baseline Visit\n             except skin cancer and cervical cancer (in situ) are allowed if at least 1 year\n             before the Baseline Visit.\n\n          4. Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g.,\n             tacrolimus, pimecrolimus), or 2) systemic antipsoriatic treatment (e.g.,\n             methotrexate, cyclosporine, hydroxyurea)\n\n          5. Use within 30 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs\n             (salicylic acid, anthralin, coal tar, calcipotriene)2) PUVA therapy, 3)  systemic\n             anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine),\n             or 4) UVB therapy.\n\n          6. Use within 30 days prior to the Screening Visit of any product containing\n             corticosteroids. Inhaled, intraocular, intranasal, etc. steroids are not allowed.\n\n          7. Subjects who have an abnormal sleep schedule or work at night.\n\n          8. Subjects with a known history of acute adrenal crisis, Addison's disease or decreased\n             adrenal output, low pituitary function or pituitary tumors.\n\n          9. Subjects who have a history of an adverse reaction to cosyntropin injection or\n             similar test reagents."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070965", 
            "org_study_id": "BDS1307"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DFD01 Spray Group 1", 
                    "DFD01 Spray Group 2"
                ], 
                "intervention_name": "DFD01 Spray", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Comp01 Lotion", 
                "intervention_name": "Comp01 Lotion", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Encinitas", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92024"
                    }, 
                    "name": "California Dermatology and Clinical Research Institute"
                }, 
                "investigator": {
                    "last_name": "Stacy Smith, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Rosa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95403"
                    }, 
                    "name": "Redwood Dermatology Research"
                }, 
                "investigator": {
                    "last_name": "Jeffrey Sugarman, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33175"
                    }, 
                    "name": "FXM Research Corp."
                }, 
                "investigator": {
                    "last_name": "Hector Wiltz, MD, CPI", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "Academic Dermatology Associates"
                }, 
                "investigator": {
                    "last_name": "Alicia Bucko, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Dermatology Consulting Services"
                }, 
                "investigator": {
                    "last_name": "Zoe Diane Draelos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19101"
                    }, 
                    "name": "Paddington Testing Company, Inc."
                }, 
                "investigator": {
                    "last_name": "Jennifer L Parish, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Tennessee Clinical Research Center"
                }, 
                "investigator": {
                    "last_name": "Michael H Gold, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "DermResearch, Inc."
                }, 
                "investigator": {
                    "last_name": "Janet DuBois, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "The University of Texas Health Science Center at Houston"
                }, 
                "investigator": {
                    "last_name": "Adelaide Hebert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katy", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77494"
                    }, 
                    "name": "Suzanne Bruce and Associates, PA The Center for Skin Research Katy/Cinco Ranch"
                }, 
                "investigator": {
                    "last_name": "Syed Ali, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_contact": {
            "email": "kgulbronson@promiuspharma.com", 
            "last_name": "Kendra Gulbronson, MS", 
            "phone": "609-282-1476"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects with HPA axis suppression", 
            "safety_issue": "Yes", 
            "time_frame": "Day 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Promius Pharma, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promius Pharma, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}